National Bleeding Disorders Foundation/X
Aug 31, 2025, 09:45
Slow Uptake of Hemophilia Gene Therapies: Challenges in Access and Adoption
National Bleeding Disorders Foundation (NBDF) shared on X:
”A new forum piece in Research and Practice in Thrombosis and Haemostasis explores the complex factors at play, from long-term efficacy and safety questions to cost, access, and patient decision-making.
Read the full open-access article.”
A recent RPTH forum article examines why the uptake of hemophilia gene therapy remains modest, citing concerns over long-term efficacy and safety, high costs, access barriers, and competition from effective non-factor therapies.
Latest news in the field of bleeding disorders featured in Hemostasis Today.
-
Nov 8, 2025, 05:31Phenotyping of Human Platelets by Daisie Yates
-
Nov 8, 2025, 04:35Inaugural Women In Hematology US Focus Meeting 2025 Officially Commenced
-
Nov 7, 2025, 06:59Stephen Cornelissen is Celebrating an Extraordinary Milestone at Australian Red Cross Lifeblood
-
Nov 7, 2025, 06:56Reza Shojaei on Leadership in the Blood and Plasma Sector
-
Nov 7, 2025, 06:52Rachel Margolis-Goodman Announces Groundbreaking Expension of Versiti Blood Research Institute
-
Nov 7, 2025, 06:46What’s New in HIT from THANZ Webinar Series
-
Nov 7, 2025, 03:30Abdallah Othman About Cardiac Vasculature
-
Nov 7, 2025, 03:29Aabha Divya: Thrilled to Share Our Latest Publication in Annals of Thoracic Surgery Short Reports!
-
Nov 7, 2025, 03:28Shantel Holcomb: Boston Scientific is Investing in Innovative Solutions to Improve Outcomes for Patients With CAD